Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSR | P00390 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | BCHE | P06276 | 2/20 | 0.41 |
| ▸ | ACHE | P22303 | 2/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL841392 | 0.87 | EGFR (0.49) | GSRKMT2ABCHEACHECHRM1 | |
| SCHEMBL3178520 | 0.81 | APP (0.46) | KMT2AMEN1GAA | |
| Bromide SCHEMBL842321 | 0.80 | TLR7 (0.45) | KMT2A | |
| SCHEMBL6094775 | 0.79 | BRD4 (0.42) | KMT2ABRD4MEN1 | |
| SCHEMBL8132565 | 0.78 | MEN1 (0.49) | KMT2ABCHEACHEBRD4MEN1 | |
| SCHEMBL562893 | 0.77 | BRD4 (0.40) | KMT2ABRD4NPC1RAB9A | |
| SCHEMBL841682 | 0.76 | MEN1 (0.49) | KMT2ABCHEACHEBRD4MEN1 | |
| SCHEMBL4199059 | 0.76 | EGFR (0.54) | GSRKMT2ABCHEACHECHRM1 | |
| SCHEMBL4199068 | 0.76 | EGFR (0.54) | GSRKMT2ABCHEACHECHRM1 | |
| SCHEMBL4771491 | 0.76 | ADORA2A (0.38) | KMT2ABRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8143270-B2 | 2-amino 1H-in-imidazo ring systems and methods | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2012-03-27 | — | — | US | disclosed |
| EP-1784180-A4 | 2-AMINO 1H IMIDAZO RING SYSTEMS AND METHODS | 3M INNOVATIVE PROPERTIES CO (US) | 2009-07-22 | — | — | EP | disclosed |
| US-20090023720-A1 | 2-Amino 1H-Imidazo Ring Systems and Methods | 3M INNOVATIVE PROPERTIES COMPANY | 2009-01-22 | — | — | US | disclosed |
| EP-1784180-A2 | 2-AMINO 1H IMIDAZO RING SYSTEMS AND METHODS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2007-05-16 | — | — | EP | disclosed |
| WO-2006029115-A2 | 2-AMINO 1H IMIDAZO RING SYSTEMS AND METHODS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2006-03-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023720-A1 | 2-Amino 1H-Imidazo Ring Systems and Methods | IL2, IL2RA, IL4I1 | GSR 1411/4885KMT2A 1860/4885BCHE 3926/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.